IgG2 Hinge Engineering for Disulfide-Homogeneous Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to address structural heterogeneity in recombinant IgG2 antibodies, leading to inconsistent pharmaceutical properties and stability, particularly due to disulfide bond formation issues during production.
Innovation Solution
Modifying the amino acid sequence of IgG2 antibodies by substitution, deletion, or insertion of residues in the heavy or light chain polypeptides to ensure a single conformational isoform is formed, primarily through interchain disulfide bonds with specific cysteine residues, thereby eliminating disulfide heterogeneity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to produce recombinant IgG2 antibodies, then production is achieved, but structural heterogeneity due to disulfide bond formation occurs
Solution Approach 1:
The patent modifies amino acid sequences in the hinge region of IgG2 antibodies, specifically changing cysteine residues to other amino acids (such as serine, alanine, or valine) to alter disulfide bond formation parameters. This prevents the formation of multiple disulfide isoforms and ensures production of a single homogeneous structural form, thereby improving both manufacturing precision and pharmaceutical property consistency
Solution Approach 2:
The patent applies localized amino acid modifications specifically in the hinge region (residues 216-238) of the heavy chain, rather than modifying the entire antibody structure. By targeting specific cysteine residues (such as Cys219, Cys220, or Cys222) for substitution, the invention achieves structural homogeneity while preserving the overall antibody function and reducing heterogeneity only where disulfide bonds cause problems
2Manufacturing precision
If amino acid modifications are made to eliminate disulfide heterogeneity, then structural homogeneity is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent incorporates amino acid modifications directly into the gene sequence used for recombinant antibody production. By designing the expression construct with the desired amino acid substitutions (such as Cys219Ser or Cys220Ala) built-in from the beginning, the homogeneous IgG2 antibody is produced directly during cell culture and expression, eliminating the need for post-production purification or separation of disulfide isoforms. This preliminary action in gene design simplifies the overall manufacturing process despite the initial molecular complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Produces structurally homogeneous IgG2 antibodies with improved stability and activity, simplifying manufacturing and processing, while maintaining consistent pharmaceutical properties over time.
Implementation Method 1
The light chain polypeptide forms an interchain disulfide bond with the heavy chain polypeptide through a C-terminal cysteine residue
Data Source
AI summary
The present invention is generally directed to methods of producing an increase in the enrichment and/or recovery of preferred forms of monoclonal antibodies. More particularly, the invention relates to methods for eliminating disulfide heterogeneity in the hinge region of recombinant IgG2 antibody proteins.